Evidence map›Paper›PMID 32393892›Full record

ArticleNature biomedical engineering2020

A co-formulation of supramolecularly stabilized insulin and pramlintide enhances mealtime glucagon suppression in diabetic pigs.

Caitlin L Maikawa, Anton A A Smith, Lei Zou, Gillie A Roth, Emily C Gale, Lyndsay M Stapleton, Sam W Baker, Joseph L Mann, Anthony C Yu, Santiago Correa and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature biomedical engineering, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
10.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 65 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Discrete, Chiral Polymer-Insulin Conjugates.Journal of the American Chemical Society · 2022
    Article
  13. Article
  14. Article
  15. Mediators of Amylin Action in Metabolic Control.Journal of clinical medicine · 2022
    Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 4 institutions in 2 countries.

Caitlin L MaikawaDepartment of Bioengineering, Stanford University, Stanford, CA, USA.
Anton A A SmithDepartment of Materials Science and Engineering, Stanford University, Stanford, CA, USA.
Lei ZouDepartment of Chemical and Biomolecular Engineering, University of Notre Dame, Notre Dame, IN, USA.
Gillie A RothDepartment of Bioengineering, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-3451-3694
Emily C GaleDepartment of Biochemistry, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-6536-3027
Lyndsay M StapletonDepartment of Bioengineering, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-8665-9687
Sam W BakerDepartment of Comparative Medicine, Stanford University, Stanford, CA, USA.
Joseph L MannDepartment of Materials Science and Engineering, Stanford University, Stanford, CA, USA.
Anthony C YuDepartment of Materials Science and Engineering, Stanford University, Stanford, CA, USA.
Santiago CorreaDepartment of Materials Science and Engineering, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0001-8230-4945
Abigail K GrosskopfDepartment of Chemical Engineering, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-0471-1825
Celine S LiongDepartment of Bioengineering, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-3186-7291
Catherine M MeisDepartment of Materials Science and Engineering, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-3330-8058
Doreen ChanDepartment of Chemistry, Stanford University, Stanford, CA, USA.
Megan TroxellDepartment of Pathology, Stanford University, Stanford, CA, USA.
David M MaahsDepartment of Pediatrics (Endocrinology), Stanford University, Stanford, CA, USA.
Bruce A BuckinghamDepartment of Pediatrics (Endocrinology), Stanford University, Stanford, CA, USA.
Matthew J WebberDepartment of Chemical and Biomolecular Engineering, University of Notre Dame, Notre Dame, IN, USA.
Eric A AppelDepartment of Bioengineering, Stanford University, Stanford, CA, USA. eappel@stanford.edu.ORCID http://orcid.org/0000-0002-2301-7126
Stanford University · USUniversity of Notre Dame · USAarhus University · DKStanford Medicine · US

Funding

Stanford Islet Research CoreP30DK116074 · NIDDK · STANFORD UNIVERSITY · PI Seung K Kim · 2017 to 2026
$19.5M
Co-Formulations of Amylin Analogues with Insulin Analogues for Treatment of DiabetesR01DK119254 · NIDDK · STANFORD UNIVERSITY · PI APPEL, ERIC ANDREW · 2019 to 2023
$2.9M
NIDDK NIH HHS P30 DK116074NIDDK NIH HHS R01 DK119254
6 · The paper itself

Abstract

Treatment of patients with diabetes with insulin and pramlintide (an amylin analogue) is more effective than treatment with insulin only. However, because mixtures of insulin and pramlintide are unstable and have to be injected separately, amylin analogues are only used by 1.5% of people with diabetes needing rapid-acting insulin. Here, we show that the supramolecular modification of insulin and pramlintide with cucurbit[7]uril-conjugated polyethylene glycol improves the pharmacokinetics of the dual-hormone therapy and enhances postprandial glucagon suppression in diabetic pigs. The co-formulation is stable for over 100 h at 37 °C under continuous agitation, whereas commercial formulations of insulin analogues aggregate after 10 h under similar conditions. In diabetic rats, the administration of the stabilized co-formulation increased the area-of-overlap ratio of the pharmacokinetic curves of pramlintide and insulin from 0.4 ± 0.2 to 0.7 ± 0.1 (mean ± s.d.) for the separate administration of the hormones. The co-administration of supramolecularly stabilized insulin and pramlintide better mimics the endogenous kinetics of co-secreted insulin and amylin, and holds promise as a dual-hormone replacement therapy.

Indexed as

Drug CompoundingAnimalsBridged-Ring CompoundsCucurbit(n)urilsDiabetes Mellitus, ExperimentalDiffusionDrug Administration RoutesDrug StabilityGlucagonHydrogen-Ion ConcentrationImidazolesInsulinIslet Amyloid PolypeptideMacrocyclic CompoundsMalePolyethylene GlycolsBridged-Ring Compoundscucurbit(7)urilCucurbit(n)urilsGlucagonImidazolesInsulinIslet Amyloid PolypeptideMacrocyclic CompoundsPolyethylene Glycolspramlintide

Identifiers

PMID32393892
PMCPMC7274092
OpenAlexW3023222482

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.